Western Standard LLC’s Neurogene NGNE Stock Holding History

Western Standard LLC’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-43,044	Closed	-$715K	–	32
2023 Q2	$715K	Buy	+43,044	New	+$706K	0.62%	24

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Western Standard LLC's NGNE Position: Q3 2023 in Review

Western Standard LLC sold out of Neurogene (NGNE) in Q3 2023, closing a stake of 43,044 shares — an estimated $715K sold.

Western Standard LLC first reported a position in NGNE in Q2 2023 and held it in 1 quarter. The position peaked at $715K in Q2 2023. 31 funds tracked by Wall St. Rank hold NGNE as of Q3 2023.

Western Standard LLC reported no remaining Neurogene position as of Q3 2023 after selling out during the quarter.
Western Standard LLC sold 43,044 Neurogene shares in Q3 2023, an estimated $715K.
Western Standard LLC first reported a position in Neurogene in Q2 2023 and held it in 1 quarter.
Western Standard LLC's Neurogene position peaked at $715K in Q2 2023.
31 funds tracked by Wall St. Rank held Neurogene as of Q3 2023.

Based on Western Standard LLC's 13F filing for Q3 2023, filed 14 Nov 2023.